Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Tree Island Steel Provides Update on Annual General Meeting of Shareholders
-
Lincoln Educational Services Corporation Schedules First Quarter 2026 Earnings Release And Conference Call
-
BGIN BLOCKCHAIN LIMITED Schedules the Fiscal Year 2025 Earnings and Conference Call on April 24, 2026
-
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Quantify Funds to Close STKd 100% NVDA & 100% AMD ETF (LAYS)
-
Zacatecas Silver Announces Investor Relations Engagement
-
TTEC Schedules First Quarter 2026 Earnings Release and Webcast of Investor Conference Call
-
Sonoco To Report First Quarter 2026 Results
-
Vera Bradley Terminates Existing Shareholder Rights Plan
-
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
-
Talen Energy Announces Pricing of Senior Notes
-
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Resear
-
QuasarEdge Acquisition Corporation Announces Exercise of Over-Allotment Option
-
SEALSQ Announces Agenda of its 2026 Annual General Meeting of Shareholders
-
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
-
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
4DMT Announces New Employment Inducement Grants
-
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
-
VALUE LINE, INC. DIVIDEND HAS JUST BEEN RAISED FROM $1.30 TO $1.40 (ANNUALIZED) – ITS 12TH CONSECUTIVE INCREASE
-
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase
-
Hingham Savings Reports First Quarter 2026 Results
-
New Era Energy & Digital Announces Appointment of Andy Casazza as Chief Corporate Officer
-
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
-
New Era Energy & Digital Announces Appointment of Andy Casazza as Chief Corporate Officer
-
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
-
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
-
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
-
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Develo
-
Long Beach City College Wins Regional Construction Awards for Campus Upgrades
-
MLG Capital Recognized by National Multifamily Housing Council as a 2026 Top 50 Owner
-
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
-
Introspect Technology Adds New ATE-on-Bench Solution for LPDDR6, DDR6, and HBM Interfaces
-
Action Target Announces Registration Is Open for 34th Annual Law Enforcement Training Camp (LETC)
-
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
-
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
-
Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details
-
Kairos Power Breaks Ground on Hermes 2 Demonstration Plant
-
Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
-
Crestwood Advisors Named Once Again to USA TODAY’s 2026 Best Financial Advisory Firms List
-
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
-
Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting
-
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
-
Pheast Therapeutics Reports Initial Phase 1a Data Showing Early Clinical Activity and Target Engagement for PHST001 at AACR 2026
-
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
-
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
-
Ohio No. 1 State in the Midwest for Business, According to CEOs Nationwide
-
Toll Brothers Announces Final Luxury Home for Sale at Freestone Station in Marietta, Georgia
-
Unicoin Foundation Debuts, Aligning Social Impact with the Future of Responsible Crypto
-
403 Auction Launches Star Trek Universe 60th Anniversary Sale in Toronto Featuring Set Items
-
JimStoppani.com Announces Summer Shred Challenge with $25,000 Grand Prize

